REGN910-3

DRUG3 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Diabetic Macular EdemaNeovascular Age-Related Macular Degeneration

Phase 1

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (Wet) Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

CompletedNCT01997164

Regeneron PharmaceuticalsDiabetic Macular Edema, Neovascular Age-Related Macular Degeneration

Start: 2014-11-30End: 2015-10-31Updated: 2016-01-12

Phase 2

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

CompletedNCT02712008

Regeneron PharmaceuticalsDiabetic Macular Edema

Start: 2016-03-02End: 2017-07-10Updated: 2018-10-03

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

CompletedNCT02713204

Regeneron PharmaceuticalsNeovascular Age-Related Macular Degeneration

Start: 2016-03-31End: 2017-10-03Updated: 2019-05-07